Minprog (Alprostadil)

Alprostadil mimics the natural prostaglandin E1 molecule. It binds to specific prostaglandin receptors on vascular smooth‑muscle cells, activates adenylate cyclase, and raises cyclic AMP levels. The increased cAMP causes smooth‑muscle relaxation, vasodilation, and inhibition of platelet aggregation, which together enhance blood flow to targeted tissues.

The dosage of Minprog is individualized. A qualified prescriber determines the appropriate amount, concentration, and administration schedule based on the patient’s condition, response, and clinical guidelines. No fixed regimen is provided in public information.

Safety data for alprostadil during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Consequently, it is generally avoided unless the potential benefit justifies the potential risk, and it should only be used under strict medical supervision.

To request Minprog, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

The primary alternative to alprostadil is nitroglycerin, another vasodilator. While both promote blood vessel relaxation, alprostadil has a stronger effect on platelet inhibition and is often preferred for peripheral arterial disease and erectile dysfunction, whereas nitroglycerin is commonly used for acute angina. Choice depends on the specific indication and patient tolerance.

Minprog must be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If the product reaches room temperature for a short period, it should be returned to controlled storage promptly.

Minprog is administered by a healthcare professional via intra‑arterial or intravenous injection. The route, infusion rate, and site of administration are selected based on the therapeutic indication and patient condition, and the procedure follows aseptic technique and institutional protocols.

The most serious adverse events include priapism (a prolonged erection lasting more than four hours), severe hypotension that can lead to dizziness or syncope, and allergic reactions ranging from mild rash to life‑threatening anaphylaxis. Immediate medical attention is required if any of these occur.

Minprog is contraindicated in patients with known hypersensitivity to alprostadil or any component of the formulation, those with severe hypotension, and individuals who have experienced priapism previously. Caution is also advised for patients on anticoagulants, as the drug may increase bleeding risk.